Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. | Zendy

E. Clarke Haley | Zendy; David E. Levy | Zendy; Thomas Brott | Zendy; G L Sheppard | Zendy; MP Wong | Zendy; Gail L. Kongable | Zendy; James C. Torner | Zendy; John R. Marler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.

Author(s) -

E. Clarke Haley,

David E. Levy,

Thomas Brott,

G L Sheppard,

MP Wong,

Gail L. Kongable,

James C. Torner,

John R. Marler

Publication year - 1992

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.23.5.641

Subject(s) - medicine , asymptomatic , tissue plasminogen activator , intracerebral hemorrhage , stroke (engine) , confidence interval , surgery , fibrinolytic agent , anesthesia , glasgow coma scale , mechanical engineering , engineering

Renewed interest in thrombolytic therapy as potential treatment for patients with acute ischemic stroke prompted a dose-escalation safety study of tissue plasminogen activator in patients with very early (less than or equal to 90 minutes; see Part I) neurological symptoms. To test whether this stringent entry window might be safely lengthened, a second study was organized to test tissue plasminogen activator in patients with symptoms of 91-180 minutes' duration before treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research